Linda M. Tharby, Chief Executive Officer of KORU Medical Systems, Inc. (NASDAQ:KRMD), executed a purchase of the company’s common stock on May 15, 2026. The transaction involved acquiring 1,191 shares at a price point of $3.92 per share, resulting in a total investment value of $4,668.
This recent acquisition marks an increase in Ms. Tharby's direct holdings. Following the purchase, she now holds a total of 620,622 shares of KORU Medical Systems common stock. The filing detailing this transaction was noted as an amendment to previous reports, correcting what was identified as a typographical error regarding the previously stated price per share.
The timing of this insider purchase is notable given recent market activity and corporate performance metrics for KRMD. As of the reporting period, KRMD shares were trading at $4 per share. Over the past year, the stock had demonstrated a 34% gain. However, this growth was tempered by a 32% decline observed year-to-date.
Operational and Financial Context
In separate but relevant company news, KORU Medical Systems Inc. announced a robust performance for its first quarter of 2026. During this period, the company achieved revenues totaling $11.8 million. This figure exceeded expectations set by analysts and represented a substantial 22% increase when compared to the revenue reported in the previous year.
Beyond top-line growth, the company's earnings per share also met established forecasts, which generally suggests solid financial health within the organization. Furthermore, KORU Medical demonstrated its commitment to advancing medical technology by presenting research concerning its FreedomEDGE infusion system at the Oncology Nursing Society Congress. The study presented highlighted successful deployment across four distinct community infusion centers located throughout the United States.
The data from this presentation indicated that 100% of doses were administered successfully, and furthermore, the infusion times strictly adhered to established clinical guidelines. These developments collectively underscore KORU Medical's operational effectiveness and its ongoing commitment to advancing medical technology solutions.
Valuation Considerations
While the recent data points suggest strong internal momentum, analysts are observing valuation metrics related to KRMD. According to an InvestingPro analysis, the stock currently appears overvalued relative to its calculated Fair Value. Despite this assessment of current pricing, the company has managed to demonstrate strong revenue growth, specifically a 23% increase over the last twelve months.
For investors seeking deeper insights into KRMD's valuation model and potential growth prospects, comprehensive research reports are available, covering not only KRMD but also more than 1,400 other US equities.